Modern management of primary T-cell immunodeficiencies

Pediatric Allergy and Immunology

Volumn 25, Issue 4, 2014, Pages 300-313

  Pachlopnik Schmid, Jana ^a   Güngör, Tayfun ^b   Seger, Reinhard ^a,b  

^a Division of Immunology Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

CID; Combined immunodeficiencies; Gene therapy; Hematopoietic stem cell transplantation; Immunoglobulin substitution; Modern management t cell defects; Severe combined immunodeficiencies, SCID; T cell immunodeficiencies; Thymus transplantation

Indexed keywords

BIOLOGICAL PRODUCT; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; CYTOKINE RECEPTOR; CYTOSTATIC AGENT; ENZYME; GROWTH FACTOR; IMMUNOGLOBULIN; IMMUNOPHILIN; INTERLEUKIN 7 RECEPTOR; PROTEIN KINASE ZAP 70; PURINE NUCLEOSIDE PHOSPHORYLASE; T LYMPHOCYTE RECEPTOR; ADENOSINE DEAMINASE; INTERLEUKIN 2 RECEPTOR GAMMA;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; B LYMPHOCYTE; CARTILAGE; CELL MATURATION; COMBINED IMMUNODEFICIENCY; DIGEORGE SYNDROME; DISEASE ACTIVITY; DYSKERATOSIS CONGENITA; GENE MUTATION; GENE THERAPY; GENETIC COUNSELING; GENETIC RISK; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HOMEOSTASIS; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; IPEX SYNDROME; JAK3 DEFICIENCY; LYMPHOCYTE PROLIFERATION; NEWBORN SCREENING; OMENN SYNDROME; PHENOTYPE; POLYENDOCRINOPATHY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY; SUPPLEMENTATION; T LYMPHOCYTE; THYMUS TRANSPLANTATION; WISKOTT ALDRICH SYNDROME; CHILD; GENE REARRANGEMENT; GENETICS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; MUTATION; TRANSPLANTATION; TRENDS;

ADENOSINE DEAMINASE; CHILD; GENE REARRANGEMENT, T-LYMPHOCYTE; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSION; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MUTATION; T-LYMPHOCYTES;

EID: 84904765129     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12179     Document Type: Article

References (76)

1. Carneiro-Sampaio M, Jacob CM, Leone CR. A proposal of warning signs for primary immunodeficiencies in the first year of life. Pediatr Allergy Immunol 2011: 22: 345-6.
2. Bousfiha AA, Jeddane L, Ailal F, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 2013: 33: 1078-87.
3. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012: 129: 607-16.
4. Lagresle-Peyrou C, Six EM, Picard C, et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet 2009: 41: 106-11.
5. Ehl S, Schwarz K, Enders A, et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest 2005: 115: 3140-8.
6. Niehues T, Perez-Becker R, Schuetz C. More than just SCID-the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2. Clin Immunol 2010: 135: 183-92.
7. van der Burg M, van Dongen JJ, van Gent DC. DNA-PKcs deficiency in human: long predicted, finally found. Curr Opin Allergy Clin Immunol 2009: 9: 503-9.
8. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001: 105: 177-86.
9. Buck D, Moshous D, de Chasseval R, et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006: 36: 224-35.
10. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005: 35: 25-30.
11. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 2004: 202: 67-83.
12. de Saint Basile G, Geissmann F, Flori E, et al. Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest 2004: 114: 1512-7.
13. Gil J, Busto EM, Garcillan B., et al. A leaky mutation in CD3D differentially affects alphabeta and gammadelta T cells and leads to a Talphabeta-Tgammadelta+B+NK+ human SCID. J Clin Invest 2011: 121: 3872-6.
14. Ben-Mustapha I, Ben-Farhat K, Guirat-Dhouib N, et al. Clinical, immunological and genetic findings of a large tunisian series of major histocompatibility complex class II deficiency patients. J Clin Immunol 2013: 33: 865-70.
15. Florian C, Bahi-Buisson N, Bienvenu T. FOXG1-related disorders: from clinical description to molecular genetics. Mol Syndromol 2012: 2: 153-63.
16. Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 2012: 69: 17-27.
17. Shiow LR, Roadcap DW, Paris K, et al. The actin regulator coronin 1A is mutant in a thymic egressdeficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol 2008: 9: 1307-15.
18. Fischer A, Picard C, Chemin K, Dogniaux S, le Deist F, Hivroz C. ZAP70: a master regulator of adaptive immunity. Semin Immunopathol 2010: 32: 107-16.
19. Arpaia E, Benveniste P, Di Cristofano A, et al. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 2000: 191: 2197-208.
20. Moshous D, Meyts I, Fraitag S, et al. Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF-alpha mAbs. J Allergy Clin Immunol 2011: 128: 847-53.
21. Marrella V, Maina V, Villa A. Omenn syndrome does not live by V(D)J recombination alone. Curr Opin Allergy Clin Immunol 2011: 11: 525-31.
22. Morgan NV, Goddard S, Cardno TS, et al. Mutation in the TCRalpha subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRalphabeta+ T cells. J Clin Invest 2011: 121: 695-702.
23. Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 2010: 207: 2073-9.
24. Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol 2011: 22: 758-69.
25. Feske S, Gwack Y, Prakriya M, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006: 441: 179-85.
26. Picard C, McCarl CA, Papolos A, et al. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. N Engl J Med 2009: 360: 1971-80.
27. 2+ revealed by human T-cell immunodeficiency. Nature 2011: 475: 471-6.
28. Nehme NT, Pachlopnik Schmid J, Debeurme F, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012: 119: 3458-68.
29. Abdollahpour H, et al. The phenotype of human STK4 deficiency. Blood 2012: 119: 3450-7.
30. Crequer A, Picard C, Patin E, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012: 122: 3239-47.
31. Yao Z, Cui Y, Watford WT, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A 2006: 103: 1000-5.
32. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 2007: 8: 37-48.
33. Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B. An update on the hyper-IgE syndromes. Arthritis Res Ther 2012: 14: 228.
34. Savage SA. Connecting complex disorders through biology. Nat Genet 2012: 44: 238-40.
35. Touzot F, et al. Function of Apollo (SNM1B) at telomere highlighted by a splice variant identified in a patient with Hoyeraal-Hreidarsson syndrome. Proc Natl Acad Sci U S A 2010: 107: 10097-102.
36. Pachlopnik Schmid J, Cote M, Menager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010: 235: 10-23.
37. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012: 119: 2754-63.
38. Sepulveda F, Debeurme F, Ménasché G, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A and STX11. Blood 2013: 121: 595-603.
39. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with Xlinked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011: 117: 1522-9.
40. Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009: 119: 1350-8.
41. Zumer K, Saksela K, Peterlin BM. The mechanism of tissue-restricted antigen gene expression by AIRE. J Immunol 2013: 190: 2479-82.
42. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011: 41: 1517-27.
43. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007: 38: 112-21.
44. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010: 116: e35-40.
45. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 2009: 3: 349-58.
46. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009: 360: 447-58.
47. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 2011: 365: 734-41.
48. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005: 105: 4743-8.
49. Pachlopnik Schmid J, Ho CH, Chretien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009: 1: 112-24.
50. Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol 2010: 135: 236-46.
51. Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: where do we stand? Br J Haematol 2013: 160: 146-52.
52. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010: 126: 602-10 e1-11.
53. Peaudecerf L, Lemos S, Galgano A, et al. Thymocytes may persist and differentiate without any input from bone marrow progenitors. J Exp Med 2012: 209: 1401-8.
54. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003: 361: 553-60.
55. Martinez-Martinez L, et al. From severe combined immunodeficiency to Omenn syndrome after hematopoietic stem cell transplantation in a RAG1 deficient family. Pediatr Allergy Immunol 2012: 23: 660-6.
56. Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006: 295: 508-18.
57. Fernandes JF, Rocha V, Labopin M, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood 2012: 119: 2949-55.
58. Straathof KC, Rocha V, Labopin M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009: 374: 912-20.
59. Gruhn B, Rocha V, Labopin M, et al. Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure. Orphanet J Rare Dis 2007: 2: 5.
60. Brown L, Rocha V, Labopin M, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011: 117: 3243-6.
61. Rao K, Rocha V, Labopin M, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005: 105: 879-85.
62. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006: 107: 1233-6.
63. Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2013: S0140-6736(13)62069-3. Epub ahead of print.
64. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009: 113: 4114-24.
65. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene 2013: 525: 170-3.
66. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010: 363: 355-64.
67. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011: 3: 97ra79.
68. Kustikova O, Brugman M, Baum C. The genomic risk of somatic gene therapy. Semin Cancer Biol 2010: 20: 269-78.
69. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A, et al. Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 2012: 24: 580-4.
70. Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminasedeficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol 2010: 10: 551-6.
71. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010: 363: 1918-27.
72. Merten OW, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011: 22: 343-56.
73. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011: 29: 731-4.
74. Puck JM. Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr 2011: 23: 667-73.
75. Gossage DL, Buckley RH. Prevalence of lymphocytopenia in severe combined immunodeficiency. N Engl J Med 1990: 323: 1422-3.
76. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005: 203: 98-109.